ABSTRACT OBJECTIVE. We evaluated the risk of altered glucose levels and new-onset diabetes (NOD) associated with statins according to glucose levels at baseline in a population treated for dyslipidemia on primary prevention for >5 years. DESIGN. The retrospective study included 308 subjects (265 on statins and 43 controls on diet) with a follow-up of 5-15 years. The cohort was classified according to glucose tolerance at both baseline and follow-up. RESULTS. The cumulative incidence of NOD was 13.6% (9.3% in controls and 13.5% in treated patients). NOD was diagnosed after 3.4±1.8 years. In the group with normal glucose levels at baseline, a family history of diabetes (OR: 3.4, 95% CI 1-14.1, p<0.020) , and in particular simvastatin and atorvastatin, was associated with increased risk of altered glucose levels or NOD. Patients who developed or maintained altered glucose levels or NOD had a poor metabolic phenotype at baseline. CONCLUSIONS. Statins were associated with an increased risk of NOD or altered glucose levels, mainly in subjects with altered glucose levels before the beginning of therapy. Poor metabolic phenotype and unhealthy behaviors or family history of diabetes contributed to that risk.
INTRODUCTION
Due to the high morbidity and mortality related to related to these pathologies (mainly coronary disease, 1 Statins represent one of the most important breakthroughs in the treatment of patients with high CV risk, as documented by many studies on both primary 2, 3 However, an association has been identified between statin therapy and new onset of type 2 diabetes mellitus (NOD), 4-8 which is 9 (FDA) issued a warning related to statin therapy and 10 Nevertheless, it is useful to remember that most of the evidence has emerged from post-hoc analyses of studies not specifically
The aim of the present study was to evaluate the long-term effect of statin therapy on glucose metabolism in a heterogeneous group of dyslipidemic primary prevention patients referred to a tertiary of NOD in patients treated with statin therapy for detection of alterations in markers of prediabetes during statin treatment on the basis of anthropometric and biochemical parameters, concomitant treatment, family history, unhealthy behaviors and risk factors as described in the Treating to New Target (TNT), Incremental Decrease in End Points Through Aggressive Lipid Lowering Trial (IDEAL) and the Stroke Prevention by Aggressive Reduction in Cholesterol 7,11-14
SUBJECTS AND METHODOLOGY
We performed a retrospective longitudinal study from 2000 to 2014 in patients referred to the Lipidology outpatient clinic of the "Ospedale Maggiore della 15 Patients were selected based on the following criteria: males and females aged 18-90 years, naïve to statin use before the baseline sample followed by continuous statin (cases) or diet patients on primary prevention; those with a known diagnosis of type 2 diabetes and/or cardiovascular diseases different from hypertension, dyslipidemia secondary to kidney failure or cystic fibrosis, family history of type 1 diabetes or active neoplasia were Changes of statin dosage or molecule were allowed and patients were scheduled as treated with the last included in the study, patients and controls had be checked and scheduled at baseline and at the last visit for family history (type 2 diabetes and dyslipidemia), lifestyle habits (smoke and alcohol consumption), evaluations of the following clinical and biochemical parameters: weight, height, waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, HbA1c, total cholesterol (T-c), High Density Lipoprotein-cholesterol (HDL-c), Low Density Lipoprotein-cholesterol (LDL-c), triglycerides (TG), serum creatinine, aspartate aminotransferase
The initial cohort was composed of 1,879 subjects, of whom 1,571 were excluded because they did not according to glucose tolerance at both baseline and subjects with normal (A) and altered glucose levels who maintained (AA) or patients whose levels returned to normal (BA), patients who developed (AB) or who maintained altered glucose levels (BB) and patients Height was measured by the Harpenden stadiometer to the nearest mm and weight by using an electronic as body weight divided by squared height (kg/m 2 SBP and DBP were measured using a mercury free -pan) with an appropriate cuff size after participants had been seated quietly for at least 15 min with their right arm supported at the level of the heart and feet NOD was diagnosed according to the American Diabetes Association (ADA) criteria for fasting plasma -during an oral glucose tolerance test (OGTT) or HbA1c
Altered glucose levels were used for individuals with impaired fasting glucose (IFG; fasting plasma mmol/l) and/or impaired glucose tolerance (IGT; 2-h 16 LDL-c was determined either by a laboratory test or with the Friedewald formula; non-HDL-c, LDL-to HDL-c ratio and T-c to HDL-c ratio were also calcuaccording to the TNT, SPARCL and IDEAL studies 7, [11] [12] [13] [14] blood pressure levels >140/90 mmHg or treatments for hypertension, BMI >30 kg/m 2 Biochemical analyses were performed using standmeasured by the gluco-oxidase colorimetric method 1c levels were measured by high-performance liquid chromatography (HPLC) using a Variant machine (Biorad, Hercules, CA); intra-and inter-assay coefficients of variation are respectively lower than -nine levels were assessed using the enzymatic method of creatinine deamidase/GLDH (Adivia Chemistryconcentration was measured by esterase and oxidase conversion (Advia 1650, Bayer Diagnostics, Newbury, enzymatic determination (Advia 1650, Bayer Diag-AST and ALT levels were measured by enzymatic
The study was conducted in accordance with the Inter-Hospital Ethic Committee (Maggiore Hospital Ethical Committee) and written informed consent
Statistical analysis
Results are expressed as mean and standard deDistributions of continuous variables were examined for skewness and were logarithmically transformed --sion analysis was used to determine the association of altered glucose levels/NOD with the odds ratio treatment with statin, alcohol, thiazide therapy and risk factors derived from TNT, IDEAL and SPRCL treatment with ezetimibe, smoking habits and years to molecules (fluvastatin + pravastatin; simvastatin, -sis was performed in the whole population or in the two subgroups (controls on diet/patients on statins) in both main effect and custom models (interaction Cox regression models were fitted to the time of -ment of the year of diagnosis of NOD was derived from the files of all patients who had obtained an exemption from payment for drugs, syringes and glucose monitoring strips because of a diagnosis of performed for the outcome NOD + altered glucose levels because the year of diagnosis of altered glucose -
RESULTS
The first dataset included 1,879 subjects of whom 1,571 patients were excluded because they did not satisfy the inclusion criteria: 1,206 subjects for a follow-up <5 years, 26 for incomplete clinical or biochemical data, 20 for statin withdrawal before 5 years and 319 for the presence of type 2 diabetes at on statin therapy and 43 on diet (controls), included 216 patients in group A (normal glucose levels) and 123 patients had a family history of type 2 diabetes With respect to therapy, 65 patients had been treated with atorvastatin, 85 with simvastatin, 62 with rosuvastatin, 37 with pravastatin and 16 with had been further treated with ezetimibe, 25 patients taking thiazide diuretics and 2 patients beta-blockers Clinical and metabolic characteristics of patients with normal and altered glucose levels at baseline Age, weight, BMI, waist circumference, SBP, DBP, fasting glucose, HbA1c and AST levels were higher in the cohort as a whole or divided according to cases Altered glucose levels at baseline were associated Clinical and metabolic characteristics of patients with normal and altered glucose levels at follow-up
At the last follow-up visit, those in group B had higher body weight, BMI, waist circumference, glucose, HbA1c, blood pressure, TG, ALT, while they had lower T-c, LDL-c, HDL-c, and T-c to HDL-c ratio By considering subjects with normal glucose levels at follow-up (AA and BA), those treated with 2 , In addition, the AB group had lower weight 1c
Risk factors associated with the development of altered glucose levels

Risk factors associated with altered glucose levels and NOD
By evaluating the whole population, family history SBP ( 
DISCUSSION
In our retrospective study on a cohort of dyslipidemic patients treated with statins or diet and with a follow-up longer than 5 years, those who developed or maintained altered glucose levels or NOD had a in particular atorvastatin, was associated with altered glucose levels or NOD in those who had altered fasting glucose at baseline, suggesting that this population A meta-analysis of 13 randomized controlled trials NOD after 4 years of statin treatment, particularly in those who were older 4 and on intensive-dose statin 5 The higher incidence in our cohort could be explained by the longer follow-up (median: 6 patients were referred to a tertiary referral center for dyslipidemia, a selection bias due to a higher risk -tion, our patients were subjected to a careful staging of CV risk factors and an OGTT was also performed -over, the incidence of NOD in patients treated with diet was higher than that reported in other studies in 17, 18 This difference could be due to difficulties in the ascertainment of the incidence of NOD in the general population and dyslipidemic patients could be a population at higher risk when diet adherence is not good, as shown in the "Primary prevention of cardiovascular disease with pravastatin 19 Cederberg et al 18 published similar data based on the follow-up of the METabolic Syndrome In Men (METSIM) study conducted in men randomly selected observed an increased risk of NOD in those treated with statins, but also a worsening of hyperglycemia at oral glucose tolerance test (OGTT) that represented a -tion in a selected population of dyslipidemic patients of both sexes on primary prevention and with a longer is that the glucose phenotype at baseline was crucial in predicting the risk of developing altered glucose levels with statins, whereas the risk was not present post hoc analysis of the patients without diabetes at baseline from both the TNT and IDEAL 20 Our analysis of anthropometric and metabolic parameters showed that patients who developed altered glucose levels or NOD had an insulin resistance central obesity and hypertension as well as lower HDL-c levels and maintained these characteristics more rapidly worsen a metabolic phenotype already 19, 21, 22 Because we also observed that a higher number of TNT risk factors increased the risk, clinicians should carefully monitor patients with this phenotype since a synergistic action A family history of type 2 diabetes is recognized demonstrated that the risk is three times higher in people who have a relative affected by type 2 diabetes and 6 times higher in people who have both parents 23, 24 In our series, a family history of type 2 diabetes should be another factor to consider in the Alcohol abuse has been identified as a possible risk factor for NOD since it results in an extreme intake of carbohydrates, obesity, increasing pancreatitis incidence and worsening of hepatic function 25 Interestingly, although we were unable to stratify daily alcohol intake due to the retrospective nature This factor should be considered in the follow-up of analyses are needed, especially since it was recently observed that a moderate reduction risk of NOD is present but confined to women with moderate levels 26 Moreover, we showed that statins, mainly atorvastatin, are linked to a higher risk of NOD or altered glucose levels in agreement with the majority of the a protective effect on glucose alteration develop- [27] [28] [29] The reason why some, but not all, statins have detrimental effects on glucose metabolism remains -nisms, other possible explanations include residual confounding factors, including a different lifestyle
We also reported a lower risk of having altered glucose levels at baseline, before any treatment with These results are in line with several observational studies that reported an inverse association between familial hypercholesterolemia and the risk of type 2 diabetes with a certain genotype-phenotype cor-30 Moreover, the SAFEHEART cohort study showed that statins do not increase the risk of type 2 diabetes mellitus in patients with familial hyper-31 These data point to the intriguing hypothesis that LDL receptor (LDLR) mutations can 30 to its retrospective nature we could not control for of altered glucose levels could not be ascertained in registries or with medical prescriptions, Cox regresAdditionally, we studied only a few controls, but this is linked to the nature of a population followed in a -nally, many risk factors including family history of
In conclusion, this study confirmed that statins are associated with an increased risk of NOD or altered glucose levels, mainly in subjects with fasting glumetabolic phenotype, lifestyle risk factors and family
